SPRY2 is differentially expressed in both lymph node and brain metastases in human breast cancer.

Shahan Mamoor, MS¹

¹shahanmamoor@gmail.com

East Islip, NY USA

Metastasis to the brain is a clinical problem in patients with breast cancer¹⁻³. We mined published microarray data^{4,5} to compare primary and metastatic tumor transcriptomes for the discovery of genes associated with brain metastasis in humans with metastatic breast cancer. We found that sprouty homolog 2, encoded by SPRY2, was among the genes whose expression was most quantitatively different in the brain metastases of patients with metastatic breast cancer. SPRY2 mRNA was present at decreased quantities in brain metastatic tissues as compared to primary tumors of the breast. Importantly, expression of SPRY2 in primary tumors was significantly correlated with patient recurrence-free survival in patients with breast cancer. Modulation of SPRY2 expression may be relevant to the biology by which tumor cells metastasize from the breast to the brain.

Keywords: breast cancer, metastasis, brain metastases, central nervous system metastases, sprouty homolog 2, SPRY2, systems biology of breast cancer, targeted therapeutics in breast cancer.

One report described a 34% incidence of central nervous system metastases in patients treated with trastuzumab for breast cancer². More recently, the NEfERT-T clinical trial⁶ which compared administration of either neratinib or trastuzumab in conjunction with paclitaxel demonstrated that in a randomized, controlled setting, in breast cancer patients treated with neratinib, not only was the incidence of central nervous system recurrence significantly lower, the time to central nervous system metastasis was significantly delayed as compared to patients administered trastuzumab⁶. The alarmingly high rate of central nervous system metastasis described, as well as data, both anecdotal² and from a randomized, controlled setting⁶ illustrating that treatment with trastuzumab may be associated with these events demands an enhanced understanding of the transcriptional makeup of brain metastatic tissues to support identification of therapeutic targets, whether they are treatment related or not. We performed a global comparative analysis of primary and metastatic tumors in patients with brain metastatic breast cancer^{4,5}. We discovered differential and decreased expression of the gene encoding sprouty homolog 2, SPRY2, in brain metastatic tissues of patients with metastatic breast cancer.

Methods

We used datasets GSE10893⁴ and GSE124648⁵ for this global differential gene expression analysis of brain metastatic breast cancer in conjunction with GEO2R. GSE10893 was generated using Agilent-011521 Human 1A Microarray G4110A technology with $n=11$ primary breast tumors and $n=4$ brain metastases from patients with breast cancer; analysis was performed using platform GPL885. GSE124648 was generated using Affymetrix Human Genome U133A array technology with $n=10$ normal breast tissues and $n=44$ lymph node metastases from patients with breast cancer; analysis was performed using platform GPL96. The Benjamini and Hochberg method of p -value adjustment was used for ranking of differential expression but raw p -values were used to assess statistical significance of global differential expression. Log-transformation of data was auto-detected, and the NCBI generated category of platform annotation was used. A statistical test was performed to evaluate whether SPRY2 gene expression was significantly different between primary tumors of the breast and brain metastases in humans with breast cancer using a two-tailed t-test. For Kaplan-Meier survival analysis, we used the Kaplan-Meier plotter online tool⁷ for correlation of SPRY2 mRNA expression levels in primary tumors of the breast with recurrence-free survival in $n=3951$ breast cancer patients.

Results

We performed global comparative transcriptome analysis of metastatic and primary tumor tissues of patients with metastatic breast, as well as normal tissues of the breast using published microarray data^{4,5} to describe the transcriptional landscape of brain metastasis in human breast cancer in an unbiased fashion and for the discovery of novel therapeutic targets.

SPRY2 is differentially expressed in the brain metastases of patients with brain metastatic breast cancer.

Through blind, systems-level analysis of published microarray data⁴, we identified sprouty homolog 2, encoded by SPRY2, as a differentially expressed gene in the brain metastatic tissues of humans with breast cancer (Table 1). When sorting each of the genes expressed in brain metastases based on significance of difference as compared to primary tumors of the breast in patients with breast cancer, SPRY2 ranked 192 out of 17418 total transcripts (Chart 1), equating to 98.9% differential expression. Differential expression of SPRY2 in the brain metastases of patients with metastatic breast cancer was statistically significant (Chart 1; $p=5.04e-04$).

SPRY2 is differentially expressed in the lymph node metastases of patients with breast cancer.

To determine whether differential expression of SPRY2 in human breast cancer could be validated in a second microarray dataset, and whether this was specific to brain metastases or could be observed in other anatomical locations, we queried a second microarray dataset⁵, here comparing normal breast tissues to lymph node metastases. Again, we identified SPRY2 as a differentially expressed gene in the lymph node metastatic tissues of patients with breast cancer (Chart 2). When sorting each of the genes expressed in lymph node metastases based on significance of difference as compared to normal breast tissues, SPRY2 ranked 171 out of 22283 total transcripts (Chart 2), equating to 99.2% differential expression. Differential expression of SPRY2 in the lymph node metastases of patients with metastatic breast cancer was statistically significant (Chart 2; $p=1.95e-12$). Thus, differential expression of SPRY2, transcriptome-wide, in metastatic tissues of women with metastatic breast cancer was conserved across two independent microarray datasets, in the brain and in the lymph nodes.

SPRY2 is expressed at lower levels in the brain metastases of patients with metastatic breast cancer.

We obtained exact mRNA expression levels for SPRY2, in primary tumors of the breast and in brain metastasis of patients with brain metastatic breast cancer to determine direction and statistical significance of change in SPRY2 expression in brain metastatic tissues. We observed significantly decreased expression of SPRY2 in the brain metastases of patients with breast cancer as compared to primary tumors of the breast: SPRY2 was expressed at -0.9 ± 0.60 arbitrary units (AU) in primary tumors of the breast, while it was expressed at -2.42 ± 0.73 AU in brain metastatic tissues (Figure 1). The difference in SPRY2 mRNA levels between primary tumors of the breast and brain metastatic tissues was statistically significant (Figure 1; $p=0.001172$).

SPRY2 expression is correlated with survival outcomes in human breast cancer.

We performed Kaplan-Meier survival analysis⁷ in 3951 breast cancer patients in total, to evaluate whether SPRY2 tumor expression was correlated with survival outcomes in breast cancer. We observed a correlation between primary tumor expression of SPRY2 and recurrence-free survival (RFS) in patients with breast cancer (Figure 2). Patients whose primary tumors expressed low levels of SPRY2 possessed median RFS of 45 months, while patients whose tumors expressed high levels of SPRY2 possessed median RFS of 54.7 months. This difference in RFS based on SPRY2 tumor expression in patients with breast cancer was statistically significant (Figure 2, Chart 3; logrank p -value: 0.035; hazard ratio: 0.89 (0.8-0.99)).

Thus, by mining published microarray data^{4,5} in an unbiased and systematic fashion, we identified sprouty homolog 2, encoded by SPRY2, as among the genes whose expression was most different, transcriptome-wide, in the brain metastases of patients with breast cancer, when compared to primary tumors of the breast and to normal breast tissues, respectively; we observed significantly decreased expression of SPRY2 in brain metastases as compared to primary tumors of the breast. Further, we found a correlation between SPRY2 expression and patient survival outcomes, as recurrence-free survival was greater in patients whose primary tumors expressed higher levels of SPRY2 as compared to patients whose primary tumors expressed lower levels of SPRY2.

Discussion

We provided evidence here that SPRY2 is among the genes whose expression is most different in the brain metastases of patients with metastatic breast cancer, that SPRY2 mRNA is present at significantly decreased quantity in brain metastatic tissues as compared to primary tumors of the breast, that SPRY2 was also differentially expressed in the lymph nodes, and that primary tumor SPRY2 expression is correlated with patient survival outcomes in human breast cancer. Evaluation of the effects of genetic depletion of SPRY2 in mouse models of metastatic breast cancer on metastasis to the central nervous system is merited. Modulation of SPRY2 expression may be relevant to the processes by which breast cancer cells exit the breast, enter the vasculature and/or lymphatics, reside in the lymph nodes, evade immune clearance, breach the blood-brain barrier and colonize the brain.

References

1. Lin, N.U., Amiri-Kordestani, L., Palmieri, D., Liewehr, D.J. and Steeg, P.S., 2013. CNS metastases in breast cancer: old challenge, new frontiers.
2. Bendell, J.C., Domchek, S.M., Burstein, H.J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R. and Winer, E., 2003. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. *Cancer*, 97(12), pp.2972-2977.
3. Tsukada, Y., Fouad, A., Pickren, J.W. and Lane, W.W., 1983. Central nervous system metastasis from breast carcinoma autopsy study. *Cancer*, 52(12), pp.2349-2354.
4. Weigman, V.J., Chao, H.H., Shabalin, A.A., He, X., Parker, J.S., Nordgard, S.H., Grushko, T., Huo, D., Nwachukwu, C., Nobel, A. and Kristensen, V.N., 2012. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. *Breast cancer research and treatment*, 133(3), pp.865-880.
5. Sinn, B.V., Fu, C., Lau, R., Litton, J., Tsai, T.H., Murthy, R., Tam, A., Andreopoulou, E., Gong, Y., Murthy, R. and Gould, R., 2019. SET ER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. *NPJ breast cancer*, 5(1), pp.1-8.
6. Awada, A., Colomer, R., Inoue, K., Bondarenko, I., Badwe, R.A., Demetriou, G., Lee, S.C., Mehta, A.O., Kim, S.B., Bachelot, T. and Goswami, C., 2016. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. *JAMA oncology*, 2(12), pp.1557-1564.
7. Györfy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q. and Szallasi, Z., 2010. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast cancer research and treatment*, 123(3), pp.725-731.

Rank: 192
Probe ID: 7219
p-value: 5.04e-04
t: 4.36
B: 0.039847
Gene: SPRY2
Gene name: sprouty homolog 2

Chart 1: SPRY2 is differentially expressed in brain metastatic breast cancer when comparing brain metastases to primary tumors of the breast.

The rank of global differential expression, the probe/transcript ID, the *p*-value with respect to differential expression transcriptome-wide, *t*, a moderated *t*-statistic, *B*, the log-odds of differential expression between the groups compared, the gene and gene name are listed in this chart.

Rank: 171
probe ID: 204011_at
p-value: 1.95e-12
t: 9.000563
B: 18.09982
Gene: SPRY2
Gene name: sprouty homolog 2

Chart 2: SPRY2 is differentially expressed in the lymph node metastases of patients with breast cancer when comparing lymph node metastases to normal breast tissues.

The rank of global differential expression, probe/transcript ID, the *p*-value with respect to differential expression transcriptome-wide, *t*, a moderated *t*-statistic, *B*, the log-odds of differential expression between the groups compared, the gene and gene name are listed in this chart.

Figure 1: SPRY2 is expressed at significantly lower levels in the brain metastases of patients with metastatic breast cancer when compared to primary tumors of the breast.

The mRNA expression level of SPRY2 in primary tumors of the breast (left) and in brain metastases of women with metastatic breast cancer (right) is graphically depicted; the result of a statistical test evaluating significance of difference in SPRY2 expression between primary tumors and brain metastases is $p=0.001172$.

Figure 2: SPRY2 primary tumor expression is correlated with recurrence-free survival in patients with breast cancer.

Depicted in this Kaplan-Meier plot is the probability of recurrence-free survival for $n=3951$ total breast cancer patients stratified into two groups, based on low or high expression of SPRY2 in patient primary tumor. The log rank p -value denoting statistical significance of difference in recurrence-free survival when comparing the two groups, as well as hazard ratio for this comparison is listed above. Listed below is the number of patients at risk (number of patients alive) per interval, after stratification based on SPRY2 expression; in the first interval, number at risk is number of patients alive; in each subsequent interval, number at risk is the number at risk less those who have expired or are censored.

1 Low SPRY2 expression: 45 months

2 High SPRY2 expression: 54.7 months

3
4 **Chart 3: Median recurrence-free survival is inferior in patients with low primary tumor expression of SPRY2.**

5 The median RFS (recurrence-free survival) of patients with low primary tumor expression of SPRY2 and
6 high primary tumor expression of SPRY2 is listed in this chart, for $n=3951$ breast cancer patients.